SCHEMBL6504170

SCHEMBL6504170

O=C(Nc1cccc(-c2n[nH]c3ccc(N4C=CNN4)cc23)c1)c1ccco1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.48
KDM4E B2RXH2 10/20 0.46
MAPT P10636 7/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GLA P06280 2/20 0.46
GAA P10253 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
POLB P06746 3/20 0.46
TSHR P16473 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
USP2 O75604 2/20 0.44
HTT P42858 2/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
HSD17B10 Q99714 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
TP53 P04637 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501248 0.87 AURKA (0.43) AURKA
SCHEMBL6509037 0.83 TTK (0.57) MAPTRXFP1AURKA
SCHEMBL6503206 0.82 MEN1 (0.44) MEN1KMT2ATDP1AURKANPC1
SCHEMBL6507670 0.81 TTK (0.45) AURKA
SCHEMBL6501210 0.80 AURKA (0.51) ITKAURKA
SCHEMBL5800211 0.80 MAPT (0.62) ITKKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL6499706 0.79 AURKA (0.50) KDM4EMAPTALDH1A1SMN1; SMN2TSHR
SCHEMBL5388392 0.79 ITK (0.53) ITKKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL6506793 0.78 ROCK2 (0.48) MAPTALDH1A1SMN1; SMN2HTTAURKA
SCHEMBL6506274 0.77 EPHX2 (0.44) TSHRKMT2ATDP1AURKANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R ITK 54/4885KDM4E 3465/4885MAPT 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.